News

The test is intended to identify non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma receptor tyrosinekinase (ALK) gene rearrangements who may benefit from Pfizer’s XalkorI (crizotinib). The

As per the agreement, the US rights to the Resolor trademark will be transferred to Shire. Resolor is approved for use in 33 countries for the symptomatic treatment

In March 2011, Epizyme and Eisai signed a global strategic alliance to discover, develop and commercialize therapeutics targeting EZH2, an epigenetic enzyme as a treatment for lymphoma and

GDNF is a naturally-occurring growth factor capable of protecting and promoting the survival of dopamine producing nerve cells. MedGenesis chairman and CEO Erich Mohr said they hope that

The FDA considers the resubmission a complete, class 2 response and assigned a new Prescription Drug User Fee Act (PDUFA) target date of 27 June 2012, the company

The rhFSH analog is developed through Trophogen’s proprietary superagonist hormone technology platform originally licensed from the National Institutes of Health. The contract manufacturing deal includes the technology transfer

Cubist and Hydra have recently identified and completed preclinical testing on a novel small molecule antagonist of the human TRPA1 channel, CB-625 (CB-189,625), and filed for regulatory approval

The certificate was granted following inspection of the facility in November 2011. Ablynx’s GMP unit will now perform release-testing on Drug Substance and Drug Product batches besides independently

The $3.1m deal is believed to help gain deep insights into the insulin-producing beta cells which are destroyed in type 1 diabetes and produce little insulin in type